Interv Akut Kardiol. 2013;12(4):207-210

Regadenoson - selective A2A adenosine for use as a pharmacological stress test in nuclear cardiology

Milan Kamínek^1,2, Iva Metelková¹, Miroslava Budíková¹, Lenka Henzlová¹, Vladimír Kincl², Jiří Ostřanský³, Martin Hutyra³, Eliška Sovová³

¹ Klinika nukleární medicíny, LF UP a FN Olomouc

² Mezinárodní centrum klinického výzkumu &ndash, Centrum molekulárního zobrazování, FN u sv. Anny, Brno

³ I. interní klinika &ndash, kardiologická LF UP a FN Olomouc

We present two case reports, demonstrating advantages of selective A2A adenosine (regadenoson) for use as a stress test in nuclear

cardiology, when conventional stress techniques may be impossible or very difficult. In the case 1, 59-year-old diabetic female patient

with a history of prior myocardial infarction was treated by direct angioplasty. Single-photon emission computed tomography (SPECT)

showed quantitative extent ischemia in the territory of infarcted vessel. Repeated coronary angiography revealed in-stent restenosis and

patient underwent bypass graft surgery. In the case 2, 55-year-old male, with several co-morbidities, had a history of conservative treatment

of the occlusion of the left circumflex artery. At present, he was referred for SPECT because of atypical chest pain. Stress test showed

a mild ischemia only and conservative strategy was recommended again.

Keywords: regadenoson, cardiac SPECT, quantification of ischemia

Published: December 1, 2013  Show citation